Sanz-Garcia, Enrique http://orcid.org/0000-0002-3119-3832
Zou, Jinfeng
Avery, Lisa
Spreafico, Anna
Waldron, John
Goldstein, David
Hansen, Aaron
Cho, B. C. John
de Almeida, John
Hope, Andrew
Hosni, Ali
Hahn, Ezra
Perez-Ordonez, Bayardo
Zhao, Zhen
Smith, Christopher
Zheng, Yangqiao
Singaravelan, Nitthusha
Bratman, Scott V.
Siu, Lillian L. http://orcid.org/0000-0002-3500-0540
Funding for this research was provided by:
Conquer Cancer Foundation
Conquer Cancer Foundation - Young investigator Award (Enrique Sanz Garcia) BMO Chair in Precision Oncology (Lillian Siu) In-kind support of Neogenomics for ctDNA analysis
Article History
Received: 3 December 2023
Revised: 11 February 2024
Accepted: 14 February 2024
First Online: 26 February 2024
Competing interests
: ESG reported research funding from Novartis. JZ is Co-inventor of patent application pending related to detection of HPV circulating cell-free DNA. It is held by the institution and is not royalty generating. AS reported a consulting/advisory role with Merck and Bristol-Myers Squibb, and grant/research funding from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, NuBiyota, Oncorus, Treadwell, Amgen, ALX Oncology, Nubiyota, Genentech, Seagen, Servier. AHansen reported receiving research funds to his institution from Karyopharm and Boston Biomedical and research funds to his institution and consulting/advising honoraria from Novartis, Genentech Inc, Hoffmann La Roche Inc, Merck Serono, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim International, AstraZeneca, Medimmune, and Pfizer. ZZ is co-inventor of patent application pending related to detection of HPV circulating cell-free DNA. It is held by the institution and is not royalty generating. CS is employee of NeoGenomics Laboratories. Scott V Bratman reported being a co-inventor on patents relating to circulating tumor DNA technologies licensed to Roche and Adela, and is a cofounder of Adela in which he carries a leadership role. LLS reported a leadership role with Treadwell Therapeutics, stock or ownership interest in Agios, consulting/advisory role with Merck, AstraZeneca/MedImmune, Roche, Voronoi Health Analytics, Oncorus, GlaxoSmithKline, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Hookipa Pharma, InterRNA, Tessa Therapeutics, Sanofi, Amgen, and research funding from Bristol Myers Squibb (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), Bayer (Inst), Amgen (Inst), Astellas Pharma (Inst), Shattuck Labs (Inst), Symphogen (Inst), AVID Radiopharmaceuticals (Inst), Mirati Therapeutics (Inst), Intensity Therapeutics (Inst), Karyopharm Therapeutics (Inst). The remaining authors did not declare any potential conflicts of interest.
: All patients signed written informed consent to participate in this study. The study was approved by the University Health Network Research Ethic Board (REB 20-5804).